Background/Objectives: Ovarian cancer is the fifth most common cancer among women, with an estimated 19,680 new cases projected in 2024. Adjuvant chemotherapy remains the standard treatment for epithelial ovarian cancers but is frequently associated with adverse events, such as chemotherapy-induced alopecia (CIA). CIA is a particularly distressing side effect that significantly affects the body image, self-esteem, and quality of life of patients. Unfortunately, CIA remains underexplored in patients with ovarian cancer. Methods: This scoping review analyzed PubMed- and EMBASE-indexed studies investigating the incidence, severity, and mechanisms of CIA in ovarian cancer patients. Eighteen studies were included for analysis. Results: Our analysis identified platinum-based compounds, taxanes, and topoisomerase I inhibitors as the agents most strongly correlated with severe alopecia, particularly in combination regimens such as carboplatin–paclitaxel (CP), and cyclophosphamide, adriamycin, and cisplatin (CAP). Among the monotherapies, taxanes, including paclitaxel and docetaxel, posed the highest risk of CIA. Mild-to-moderate alopecia was observed in patients treated with gemcitabine or pegylated liposomal doxorubicin. Alternative factors such as dosing schedules and prior chemotherapy exposure also significantly influence CIA severity. Conclusions: Given the profound psychosocial impact of CIA, optimizing treatment protocols to reduce the severity of alopecia without compromising therapeutic efficacy is crucial. These findings offer insights that may guide future therapeutic strategies for improving patient outcomes and quality of life.
Cannabidiol (CBD) is a non-intoxicating phytocannabinoid with increasingly recognized effects on cutaneous and hair follicle (HF) biology. This narrative review evaluates CBD-responsive signaling and its intersection with transcriptional, epigenetic, and post-transcriptional mechanisms relevant to HF cycling and alopecia, with particular emphasis on the hierarchy of experimental evidence. Available data indicate that CBD does not exert a uniformly pro-growth effect, but instead produces concentration-, compartment-, and context-dependent responses. In human HFs, submicromolar CBD primarily demonstrates anti-inflammatory activity, whereas micromolar exposure suppresses hair shaft production and promotes catagen through TRPV4-dependent Ca2+ signaling. CBD also modulates adenosine and Wnt/β-catenin pathways and can restore β-catenin expression in human dermal papilla cells under inhibitory conditions. Beyond acute receptor signaling, CBD influences DNA methylation, histone modifications, miRNA networks, and transcriptional regulators including PPARγ and AhR. However, most of this evidence derives from non-follicular systems, and direct CBD-induced epigenetic remodeling of human HFs has not been demonstrated. Among alopecia subtypes, AGA has the strongest mechanistic and preliminary clinical rationale, whereas evidence in AA and scarring alopecia remains largely indirect. Translation is further limited by uncertain intrafollicular CBD exposure, formulation-dependent delivery, and the absence of controlled clinical efficacy data. CBD should therefore be viewed as a context-dependent regulator of follicular signaling rather than an established hair growth treatment. Future studies should define follicular pharmacokinetics, establish concentration–response relationships, and test pathway causality in intact human HFs and disease-specific models.
Androgenetic Alopecia (AGA) is the most common cause of alopecia in males and females. Minoxidil and finasteride are the only FDA approved treatm | POSTER